Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
NCT05819138Phase 3Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jun 2023
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 1 diabetes mellitus (T1D) comparing Semaglutide with Placebo (2 arms). Primary endpoints: Ascending Aortic Pulse Wave Velocity at month 8, Carotid and Femoral Artery Pulse Wave Velocity at month 8 and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05819138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819138.